KRAS and lung adenocarcinoma: Zhu et al. derived data from the AACR GENIE 9.0 public database and showed that KRAS mutations in the USA concern 87% of pancreatic ductal adenocarcinoma, 43% of colorectal cancer, and 33% of lung adenocarcinoma patients [35].